TY - JOUR
T1 - Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
AU - Fonseca de Freitas, Daniela
AU - Kadra-Scalzo, Giouliana
AU - Agbedjro, Deborah
AU - Francis, Emma
AU - Ridler, Isobel
AU - Pritchard, Megan
AU - Shetty, Hitesh
AU - Segev, Aviv
AU - Casetta, Cecilia
AU - Smart, Sophie E.
AU - Downs, Johnny
AU - Christensen, Søren Rahn
AU - Bak, Nikolaj
AU - Kinon, Bruce J.
AU - Stahl, Daniel
AU - MacCabe, James H.
AU - Hayes, Richard D.
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2022/4
Y1 - 2022/4
N2 - Background: A proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment. Knowledge of the sociodemographic and clinical factors predicting clozapine response may be useful in developing personalised approaches to treatment. Methods: This retrospective cohort study used data from the electronic health records of the South London and Maudsley (SLaM) hospital between 2007 and 2011. Using the Least Absolute Shrinkage and Selection Operator (LASSO) regression statistical learning approach, we examined 35 sociodemographic and clinical factors’ predictive ability of response to clozapine at 3 months of treatment. Response was assessed by the level of change in the severity of the symptoms using the Clinical Global Impression (CGI) scale. Results: We identified 242 service-users with a treatment-resistant psychotic disorder who had their first trial of clozapine and continued the treatment for at least 3 months. The LASSO regression identified three predictors of response to clozapine: higher severity of illness at baseline, female gender and having a comorbid mood disorder. These factors are estimated to explain 18% of the variance in clozapine response. The model’s optimism-corrected calibration slope was 1.37, suggesting that the model will underfit when applied to new data. Conclusions: These findings suggest that women, people with a comorbid mood disorder and those who are most ill at baseline respond better to clozapine. However, the accuracy of the internally validated and recalibrated model was low. Therefore, future research should indicate whether a prediction model developed by including routinely collected data, in combination with biological information, presents adequate predictive ability to be applied in clinical settings.
AB - Background: A proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment. Knowledge of the sociodemographic and clinical factors predicting clozapine response may be useful in developing personalised approaches to treatment. Methods: This retrospective cohort study used data from the electronic health records of the South London and Maudsley (SLaM) hospital between 2007 and 2011. Using the Least Absolute Shrinkage and Selection Operator (LASSO) regression statistical learning approach, we examined 35 sociodemographic and clinical factors’ predictive ability of response to clozapine at 3 months of treatment. Response was assessed by the level of change in the severity of the symptoms using the Clinical Global Impression (CGI) scale. Results: We identified 242 service-users with a treatment-resistant psychotic disorder who had their first trial of clozapine and continued the treatment for at least 3 months. The LASSO regression identified three predictors of response to clozapine: higher severity of illness at baseline, female gender and having a comorbid mood disorder. These factors are estimated to explain 18% of the variance in clozapine response. The model’s optimism-corrected calibration slope was 1.37, suggesting that the model will underfit when applied to new data. Conclusions: These findings suggest that women, people with a comorbid mood disorder and those who are most ill at baseline respond better to clozapine. However, the accuracy of the internally validated and recalibrated model was low. Therefore, future research should indicate whether a prediction model developed by including routinely collected data, in combination with biological information, presents adequate predictive ability to be applied in clinical settings.
KW - Refractory psychosis
KW - clorazil
KW - health records
KW - machine learning
KW - zaponex
UR - http://www.scopus.com/inward/record.url?scp=85125539545&partnerID=8YFLogxK
U2 - 10.1177/02698811221078746
DO - 10.1177/02698811221078746
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35212240
AN - SCOPUS:85125539545
SN - 0269-8811
VL - 36
SP - 498
EP - 506
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 4
ER -